JP2021072800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021072800A5 JP2021072800A5 JP2021002759A JP2021002759A JP2021072800A5 JP 2021072800 A5 JP2021072800 A5 JP 2021072800A5 JP 2021002759 A JP2021002759 A JP 2021002759A JP 2021002759 A JP2021002759 A JP 2021002759A JP 2021072800 A5 JP2021072800 A5 JP 2021072800A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- solvate
- acceptable salt
- pharmaceutically acceptable
- oligonucleotide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 19
- 101000930910 Homo sapiens Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 claims 9
- 230000000295 complement effect Effects 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 5
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 claims 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 2
- 238000010934 O-alkylation reaction Methods 0.000 claims 2
- 206010018464 Glycogen storage disease type I Diseases 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000011460 glycogen storage disease due to glucose-6-phosphatase deficiency type IA Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023137828A JP2023159397A (ja) | 2018-03-09 | 2023-08-28 | 糖原病Ｉａ型治療薬 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018043524 | 2018-03-09 | ||
| JP2018043524 | 2018-03-09 | ||
| JP2018128015 | 2018-07-05 | ||
| JP2018128015 | 2018-07-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505066A Division JP6884268B2 (ja) | 2018-03-09 | 2019-03-05 | 糖原病Ｉａ型治療薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023137828A Division JP2023159397A (ja) | 2018-03-09 | 2023-08-28 | 糖原病Ｉａ型治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021072800A JP2021072800A (ja) | 2021-05-13 |
| JP2021072800A5 true JP2021072800A5 (enExample) | 2022-02-08 |
Family
ID=67845726
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505066A Active JP6884268B2 (ja) | 2018-03-09 | 2019-03-05 | 糖原病Ｉａ型治療薬 |
| JP2021002759A Pending JP2021072800A (ja) | 2018-03-09 | 2021-01-12 | 糖原病Ｉａ型治療薬 |
| JP2023137828A Pending JP2023159397A (ja) | 2018-03-09 | 2023-08-28 | 糖原病Ｉａ型治療薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505066A Active JP6884268B2 (ja) | 2018-03-09 | 2019-03-05 | 糖原病Ｉａ型治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023137828A Pending JP2023159397A (ja) | 2018-03-09 | 2023-08-28 | 糖原病Ｉａ型治療薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11958878B2 (enExample) |
| EP (1) | EP3763815A4 (enExample) |
| JP (3) | JP6884268B2 (enExample) |
| KR (2) | KR102398295B1 (enExample) |
| CN (2) | CN115976028B (enExample) |
| TW (3) | TWI760600B (enExample) |
| WO (1) | WO2019172286A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7636333B2 (ja) * | 2019-09-10 | 2025-02-26 | 第一三共株式会社 | 肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法 |
| WO2021075538A1 (ja) | 2019-10-18 | 2021-04-22 | 第一三共株式会社 | 二環性ホスホロアミダイトの製造方法 |
| CN118852286A (zh) * | 2021-01-14 | 2024-10-29 | 施能康生物科技有限公司 | 化合物、缀合物及其用途 |
| JP2024522852A (ja) * | 2021-06-24 | 2024-06-21 | イーライ リリー アンド カンパニー | 新規治療用送達部分及びその使用 |
| JP2024532271A (ja) | 2021-08-30 | 2024-09-05 | ホンジーン バイオテック コーポレイション | 官能化ｎ－アセチルガラクトサミンアナログ |
| US11993626B2 (en) | 2021-12-15 | 2024-05-28 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
| AU2023234185A1 (en) | 2022-03-16 | 2024-10-03 | Daiichi Sankyo Company, Limited | siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 |
| WO2023176863A1 (ja) | 2022-03-16 | 2023-09-21 | 第一三共株式会社 | ＲＮＡｉ活性を有する化学修飾オリゴヌクレオチド |
| WO2023225650A1 (en) * | 2022-05-19 | 2023-11-23 | Olix Us, Inc. | Linkers coupling functional ligands to macromolecules |
| TW202430499A (zh) | 2022-10-05 | 2024-08-01 | 日商第一三共股份有限公司 | 具有２分支型之ｎ－乙醯基－ｄ－半乳糖胺結構之化合物的製造方法 |
| US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0787982A (ja) | 1993-01-29 | 1995-04-04 | Sankyo Co Ltd | 修飾オリゴデオキシリボヌクレオチド |
| CA2162361C (en) * | 1993-05-11 | 2008-10-21 | Ryszard Kole | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| US6096881A (en) | 1997-05-30 | 2000-08-01 | Hybridon, Inc. | Sulfur transfer reagents for oligonucleotide synthesis |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| RU2233844C2 (ru) | 1999-02-12 | 2004-08-10 | Санкио Компани Лимитед | Новые нуклеозидные и олигонуклеотидные аналоги |
| US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| JP2001267074A (ja) | 2000-03-22 | 2001-09-28 | Fuji Photo Film Co Ltd | 有機発光素子 |
| CA3001404C (en) | 2002-11-25 | 2020-07-28 | Masafumi Matsuo | Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
| US20050261233A1 (en) | 2004-04-21 | 2005-11-24 | Sanjay Bhanot | Modulation of glucose-6-phosphatase translocase expression |
| US7323308B2 (en) | 2004-09-03 | 2008-01-29 | Affymetrix, Inc. | Methods of genetic analysis of E. coli |
| US8178503B2 (en) | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| WO2008109366A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| US12129514B2 (en) * | 2009-04-30 | 2024-10-29 | Molecular Loop Biosolutions, Llc | Methods and compositions for evaluating genetic markers |
| KR20120093138A (ko) | 2009-06-17 | 2012-08-22 | 콜드스프링하버러보러토리 | 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법 |
| WO2011053614A1 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Crystalline cdm-nag and methods for producing same |
| EP2616543A1 (en) | 2010-09-15 | 2013-07-24 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
| PL2718437T3 (pl) | 2011-06-10 | 2019-01-31 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby leczenia wrodzonej ślepoty Lebera |
| TR201809173T4 (tr) * | 2011-12-08 | 2018-07-23 | Sarepta Therapeutics Inc | İnsan LMNA'sını hedef alan oligonükleotid analogları. |
| AU2013240200B2 (en) * | 2012-03-28 | 2016-10-20 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for the collection and isolation of nucleic acids from biological specimens |
| US20150273016A1 (en) | 2012-10-17 | 2015-10-01 | Fondazione Telethon | Gene therapy for glycogen storage diseases |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| WO2014109384A1 (ja) | 2013-01-10 | 2014-07-17 | 塩野義製薬株式会社 | 架橋型核酸誘導体の製造方法 |
| MX2015009056A (es) | 2013-01-30 | 2015-10-05 | Hoffmann La Roche | Conjugados de oligonucleotidos de acido nucleico bloqueado y carbohidratos. |
| BR112015027322A8 (pt) * | 2013-05-01 | 2018-01-02 | Isis Pharmaceuticals Inc | Compostos antissenso conjugados e sua utilização |
| TW201534578A (zh) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| EP4039278A1 (en) | 2013-07-11 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| KR20160083876A (ko) * | 2013-11-14 | 2016-07-12 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | ApoB 안티센스 접합체 화합물 |
| WO2015081101A1 (en) | 2013-11-26 | 2015-06-04 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Adeno-associated virus vectors for treatment of glycogen storage disease |
| WO2015105083A1 (ja) | 2014-01-07 | 2015-07-16 | 塩野義製薬株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
| CN106795200B (zh) | 2014-10-10 | 2020-06-19 | 豪夫迈·罗氏有限公司 | Galnac亚磷酰胺、其核酸缀合物及其用途 |
| US10415044B2 (en) | 2014-12-23 | 2019-09-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adeno-associated virus vectors encoding modified G6PC and uses thereof |
| JP6784750B2 (ja) | 2015-07-31 | 2020-11-11 | アークトゥルス セラピューティクス， インコーポレイテッド | 薬物送達のためのマルチリガンド剤 |
| BR112018008971A2 (pt) * | 2015-11-06 | 2018-11-27 | Crispr Therapeutics Ag | materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a |
| MX378999B (es) | 2015-11-16 | 2025-03-10 | Hoffmann La Roche | Fosforamidita de agrupacion de n-acetilgalactosamina (galnac). |
| CA3005245A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of alagille syndrome |
| EP3409780B1 (en) | 2016-01-29 | 2021-01-20 | Kyowa Kirin Co., Ltd. | Nucleic acid complex |
| US10731546B2 (en) | 2017-02-06 | 2020-08-04 | Borgwarner Inc. | Diffuser in wastegate turbine housings |
| KR102520654B1 (ko) | 2017-03-10 | 2023-04-10 | 고쿠리츠켄큐카이하츠호진 고쿠리츠 세이쿠이료켄큐센타 | 안티센스 올리고뉴클레오티드 및 당원병 Ia형 예방 또는 치료용 조성물 |
| JP6591515B2 (ja) | 2017-12-07 | 2019-10-16 | 東芝テック株式会社 | 印刷装置、制御方法及びコンピュータプログラム |
-
2019
- 2019-03-05 KR KR1020207018195A patent/KR102398295B1/ko active Active
- 2019-03-05 WO PCT/JP2019/008713 patent/WO2019172286A1/ja not_active Ceased
- 2019-03-05 CN CN202310034281.1A patent/CN115976028B/zh active Active
- 2019-03-05 KR KR1020217034642A patent/KR20210130854A/ko not_active Withdrawn
- 2019-03-05 JP JP2020505066A patent/JP6884268B2/ja active Active
- 2019-03-05 EP EP19763548.5A patent/EP3763815A4/en active Pending
- 2019-03-05 CN CN201980006746.4A patent/CN111511915A/zh active Pending
- 2019-03-05 US US16/966,132 patent/US11958878B2/en active Active
- 2019-03-08 TW TW108107814A patent/TWI760600B/zh active
- 2019-03-08 TW TW110137469A patent/TW202202622A/zh unknown
- 2019-03-08 TW TW112150508A patent/TW202417628A/zh unknown
-
2021
- 2021-01-12 JP JP2021002759A patent/JP2021072800A/ja active Pending
-
2023
- 2023-08-28 JP JP2023137828A patent/JP2023159397A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021072800A5 (enExample) | ||
| TWI826365B (zh) | α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法 | |
| JP2016513976A5 (enExample) | ||
| BR112020020220A2 (pt) | Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b | |
| IL310631A (en) | Nucleic acid molecule to reduce papd5 and papd7 mRNA to treat hepatitis b infection | |
| JP2014504857A (ja) | ロックドヌクレオチドを含むｍｉｃｒｏＲＮＡ阻害剤 | |
| JP2025039668A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| CN111655851A (zh) | 靶向srebp1的反义寡核苷酸 | |
| JP2025072578A (ja) | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 | |
| JP2020521491A5 (enExample) | ||
| US20060263422A1 (en) | Pharmaceutical composition containing decoy and use of the same | |
| CN114829599A (zh) | Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| WO2021132591A1 (ja) | エクソン５０のスキッピングを誘導するアンチセンス核酸 | |
| JP2024530169A (ja) | 方法 | |
| JP2025094072A (ja) | Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用 | |
| CN114867856A (zh) | Saraf抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| CN113330118A (zh) | 靶向card9的反义寡核苷酸 | |
| Kiely | Recent advances in antisense technology | |
| JP2024540271A (ja) | アポリポタンパク質ｅ４発現を調節するためのオリゴヌクレオチド | |
| JP2023526096A (ja) | Ｃａｒｄ９のスプライス調節のためのオリゴヌクレオチド | |
| JPWO2019140231A5 (enExample) | ||
| US11898145B2 (en) | Enhanced oligonucleotides for inhibiting RTEL1 expression | |
| WO2024245424A1 (zh) | 一种用于免疫类疾病的双链核苷酸化合物及其应用 | |
| HK40077333A (en) | Use of saraf inhibitors for treating hepatitis b virus infection | |
| WO2023111210A1 (en) | Combination of oligonucleotides for modulating rtel1 and fubp1 |